Trousseau syndrome

Trousseau syndrome It is also known as “migratory superficial thrombophlebitis”, “carcinogenic thrombophlebitis 'and'tumor-associated thromboembolism'.

What is Trousseau syndrome?

Trousseau syndrome is an acquired blood coagulation disorder that causes migratory thrombophlebitis (inflammation from a vein due to a blood clot).

Although not always associated with an intern malignancy, many cases show an underlying Cancer.

The syndrome is characterized by the development of recurrent Superficial thrombophlebitis in any of the arterial or venous system. The lesions appear as red, swollen lines or lumps in the fat under the skin. They can occur on the trunk or extremities and are similar to those found in cellulite, erythema knotty lymphangitisand vasculitis.

What is the cause of Trousseau syndrome?

Approximately 50% of patients with Trousseau syndrome have an associated cancer. Pancreatic cancer appears to be associated with the highest risk of Trousseau syndrome, but other tumors, particularly adenocarcinomas (cancers that develop in the lining or inner surface of an organ), can also cause the syndrome. Lung cancers are commonly reported.

The actual mechanism for blood coagulation in Trousseau syndrome is believed to be due to an imbalance in the coagulation cascade induced by the underlying malignancy. The tumor secretes a variety of substances that have a detrimental effect on the blood coagulation process.

What is the treatment for Trousseau syndrome?

The main goal of treatment is to treat the underlying cancer. Once the cancer is removed or placed in remission, the symptoms and signs of Trousseau syndrome often resolve.

Heparin-based anticoagulation can be used to prevent blood clots and can be used as primary treatment for thromboembolic events associated with malignancy such as Trousseau syndrome. These conditions do not respond to vitamin K antagonists such as warfarin.